Brand dynamics
Group Real-Time Dynamics And Cutting-Edge Information In The Field Of One Health
Development and Public Welfare Go Hand in Hand: Healthy Yuan and Lizhu Group Rank Among Top 10 in 2022 Pharmaceutical Corporate Social Responsibility Survey
Published Time：
2023-08-23
Recently, Southern Weekend published In 2022, the Southern Weekend's China Corporate Social Responsibility Survey list included Joincare Pharmaceutical Group Industry Co., Ltd. and its holding company, Lizhu Pharmaceutical Group Co., Ltd., among the top ten pharmaceutical companies in terms of social responsibility scores, ranking fourth and first respectively.
It is understood that Southern Weekend's China Corporate Social Responsibility Survey keeps pace with the times, and after more than 20 years of continuous adjustment and upgrading, it has become a "yardstick" for the development of corporate social responsibility in China, serving as a "reference line" for Chinese companies in practicing social responsibility. The list selected 50 listed companies in the A-share pharmaceutical industry for evaluation, based on three dimensions: industry scale, national economic status, and social responsibility sensitivity, to screen out excellent Chinese companies that shoulder social responsibility under high-quality development.
Corporate social responsibility is becoming part of the core socialist values system in the new era, and an important indicator for all sectors of society to identify and judge the core competitiveness of an enterprise. Social responsibility has undergone a gradual transformation from simple to complex within enterprises, with Chinese companies starting with practical actions such as concept promotion, information disclosure, regular reports, and public welfare activities, continuously deepening into different issue areas of social responsibility practice, and pushing corporate social responsibility in China to a higher strategic level.
Over the years, under the leadership of Chairman Zhu Baoguo, Jiankangyuan and Lizhu Group have maintained excellent performance, focusing on their own development while actively exploring the concept of sustainable development and innovation, and consistently adhering to social public welfare undertakings and fulfilling their responsibilities as pharmaceutical companies.
Under the call of national policies, Jiankangyuan and Lizhu Group have combined their industrial advantages to continuously promote the "Universal Chronic Disease Prevention and Control Public Welfare Project." From the end of 2018 to the present, Jiankangyuan and Lizhu Group have successively carried out the "Universal Chronic Disease Prevention and Control Public Welfare Project" in Sichuan Province, Shanxi Province, Tibet Autonomous Region, Jiangxi Province and other regions, providing necessary medicines and other materials to chronic disease patients in remote areas, reducing their medical burden, further improving the accessibility of medicines, and contributing to rural revitalization.
Currently, China's pharmaceutical industry is ushering in an era of transformation, upgrading, and innovation-driven development. Jiankangyuan and Lizhu Group will continue to focus on the clinical needs of patients, focus on pharmaceutical innovation and research and development, achieve steady growth in performance; at the same time, actively practice corporate social responsibility, benefit the people with practical actions, and promote the development of Healthy China.
Quick Navigation
+86 755-33268688 | Service Hotline
Official WeChat Official Account
Copyright © 2025 Joincare Pharmaceutical Group Industry Co., Ltd. ALL Rights Reserve.